Organisation paid for research Program year 2022 Source: CMS Open Payments

Riverside Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$504,970

46 payments

Through program year 2022, Riverside Clinical Research LLC is reported as receiving $504,970 in research payments, across 46 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $1,500 1
2021 Research $265,985 25
2020 Research $182,053 16
2019 Research $55,432 4

Breakdown

Who paid Research payments · program years 2019–2022
  1. Gilead Sciences, Inc. $401,753 34 payments
  2. Eli Lilly and Company $86,033 5 payments
  3. Biohaven Pharmaceuticals, Inc. $17,184 7 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $68,271 1 payment
  2. TBC Hepatic Impairment $67,533 1 payment
  3. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Subjects with Normal and Impaired Hepatic Function $63,695 1 payment
  4. A Phase 1b, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Effect of Selonsertib on Renal Function as Assessed by Markers of Glomerular Filtration Rate in Subjects with Chronic Kidney Disease $35,286 1 payment
  5. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $28,967 1 payment
  6. A Phase 1 Open-Label, Parallel-Design, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Participants with Normal Renal Function and Severe Renal Impairment $25,495 1 payment
  7. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Subjects with Normal and Impaired Hepatic Function $20,036 1 payment
  8. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $16,059 6 payments
  9. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-6207 in Subjects with Normal and Impaired Hepatic Function $15,780 1 payment
  10. A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $14,292 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record